Albireo Pharma Inc

Albireo Pharma — Biodel — Merger or Acquisition (May 2016)

41 slides from Albireo Pharma's merger presentation, May 25, 2016

  1. Slide 1: Biodel Inc and Albireo Limited Share Exchange Agreement

    SBIODEL Biodel Inc and Albireo Limited Share Exchange Agreement NASDAQ: BIOD | May 25, 2016 Albireo

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements ‘Cera stalements contained inthis communication regarding mates that ae no storia fats are fxvare-looking statements within the meaning of Section 27€ af the ‘Socuiles and Exchange Act of 1934, a5 amended, and the Privato Socurtos iigation Rofo Ac

  3. Slide 3: Additional Information and Where You Can Find It

    Additional Information and Where You Can Find It | ‘Tris presentation may be deemed to be solicitation material in respect of the proposed transaction between Biodel Inc. (Biodel) and Albireo Limited (Albieo) and Albeo stockholders. In connection withthe proposed transaction between Biodel and Albeo

  4. Slide 4: Biodel - Albireo Share Exchange Agreement

    Biodel - Albireo Share Exchange Agreement + Follows Biodel's extensive review of strategic alternatives + All-stock transaction: Biodel to acquire all outstanding shares of Albireo in exchange for newly issued shares of Biodel common stock + Biodel stockholders will own approximately 32.875% and Alb

  5. Slide 5: Biodel - Albireo Combination

    Biodel - Albireo Combination + NASDAQ-listed company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, as well as chronic constipation, bile acid malabsorption disease and NASH + Lead asset, A4250, is a first-in-class product candidate in Phase 2 deve

  6. Slide 6: Biodel - Albireo Leadership

    Biodel - Albireo Leadership + Combined company will be led by an experienced management team associated with multiple successful NDAs/EMAs and marketed products Ron Cooper — President and CEO Former President of Europe, Bristol-Myers Squibb + Board to be comprised of seven directors, five from Albir

  7. Slide 7: Hope for Children with Orphan Liver Diseases Through Bile Acid Modulation

    Hope for Children with Orphan Liver Diseases Al b Q Through Bile Acid Modulation Ire

  8. Slide 8: Albireo

    Albireo Innovative Science + Deep Pipeline + Experienced Management + Leader in the development of bile acid modulators to treat liver and GI diseases * Three clinical assets, including lead Phase 2 orphan product candidate and Phase 3 constipation product candidate + Multiple near-term inflection o

  9. Slide 9: Highly Experienced Management Team

    Highly Experienced Management Team Ron Cooper Kristina Torfgard, Ph.D. President and CEO VP, Clinical and Regulatory Affairs ) Jan Mattsson, Ph.D. Pete Zorn Chief Operating Officer SVP, Corporate (Co-founder) Development and General Counsel |) Per-Goran Gillberg, Ph.D. Carsten Dehning VP, Developmen

  10. Slide 10: A Robust Pipeline Targeting Liver and GI Diseases and Disorders

    A Robust Pipeline Targeting Liver and GI Diseases and Disorders Lead Program: Eiicelite > Pisses D> Phase? D> Phases J IBAT inhibitor EE| Ph2 data expected 2H 2016 Additional Clinical Programs: tA tee Albireo<

  11. Slide 11: Pediatric Orphan Opportunities Provide Foundation for Albireo Thesis

    Pediatric Orphan Opportunities Provide Foundation for Albireo Thesis ©2016 Albiteo Limited, All ight reserve.

  12. Slide 12: A4250 for Orphan Pediatric Liver Diseases

    Wi) 4250 for Orphan Pediatric See Liver Diseases BBIoDEL Albireg<

  13. Slide 13: Positioned to Become First Drug Approved for Progressive Familial Intrahepatic Cholestasis

    Positioned to Become First Drug Approved for Progressive Familial Intrahepatic Cholestasis + The market opportunity... © Multiple pediatric orphan liver diseases and disorders with no approved drugs; lifetime treatment + The science... © Elevated serum bile acids linked to both progressive liver dis

  14. Slide 14: Inhibits Bile Acid Re-uptake from the Intestine to Reduce Bile Acids in the Liver

    Inhibits Bile Acid Re-uptake from the Intestine to Reduce Bile Acids in the Liver + ~ 95% of bile acids (BA) pumped from small intestine to liver, IBAT key mediator + Inhibitors selectively reduce BA re-uptake and increase colonic BA + Cholestatic liver disease patients reduced liver and serum bile

  15. Slide 15: Commercially Attractive Opportunities to Treat Rare Diseases with No Approved Drug Options

    Commercially Attractive Opportunities to Treat Rare Diseases with No Approved Drug Options Target Pediatric Cholestatic Biliary Atresia Indication Pruritus Wy PESTS Genetic abnormality; Debilitating itching arising _ Blocking or absence of the cholestasis leads tot bile _with cholestasis large bile

  16. Slide 16: Use of Bile Diversion Surgery Supports IBAT Inhibition Rationale to Treat PFIC

    Use of Bile Diversion Surgery Supports IBAT Inhibition Rationale to Treat PFIC Procedure for bile to drain outside the body around the clock into a stoma bag * Normalization of serum bile acids by PEBD indicates an excellent long-term outcome in children with PFIC (Schukfeh, et al. 2012) Bilirubin (

  17. Slide 17: Preclinical and Early Clinical Data Provide Proof of Principle and Mechanism

    Preclinical and Early Clinical Data Provide Proof of Principle and Mechanism Preclinical Cholestatic Liver Disease Model | Liver Enzymes 1000 ALT (U/L) 360 ALP (UIL) 800 600 400 200 2weeks 4weeks ° 2weeks 4 weeks *p< 0.08 © Control ALT. alanine aminotransferase mm A4250 ALP: alkaline phosphatase -~

  18. Slide 18: Phase 1 Serum and Fecal Bile Acid Data Support Phase 2 Dosing

    Phase 1 Serum and Fecal Bile Acid Data Support Phase 2 Dosing 14mg A4250 3mg A4250 120 P0901 a 12 g 2 s 3 1 100 é 1 100 g 7 sg 2 <= 0 8 ze of 3% gi 33 go 32 oo SE 32 o SE 3 Rs se 53 2 =8 as 0 8 7. one ¢ & é Hl 20 Fy 20 a o = 0 mmiPiaceto MNBL mg A4250 MmPlacebo MNS. mg A4250 + Plasma bil acid reduct

  19. Slide 19: Study in Adults with PBC to Support Pediatric Development

    Study in Adults with PBC to Support Pediatric Development First Cohort Data Shows Dramatic Effect on Pruritus + Investigator-Initiated Ph2 Primary Biliary Cirrhosis study © Crossover design, 3x4 weeks treatment (cholestyramine x A4250 x cholestyramine) 0 1.5mg A4250 QD for 1 wk + 3mg A4250 QD for 3

  20. Slide 20: Ongoing Phase 2 Study in Ped. Chol. Liver Disease

    Ongoing Phase 2 Study in Ped. Chol. Liver Disease Designed to Support Broad Pivotal Development Key inclusion criteria © Diagnosis of pruritus due to chronic cholestasis (eg., PFIC, Biliary Atresia, Alagille syndrome (ALGS), primary sclerosing cholangitis (PSC)) ‘© Serum total bile acids at least 2x

  21. Slide 21: Initial Observations from Open Label Pediatric Study

    Initial Observations from Open Label Pediatric Study Cohort 1 (0.01 mg/kg) and Cohort 2 (0.03 mg/kg) Expectations for Cohorts 1 and 2 (low dose) + Favorable safety and tolerability profile + Modest effect on efficacy measures until higher dose cohorts Preliminary Observations* in Cohorts 1 and 2 + N

  22. Slide 22: Staged Clinical Development Approach to Leverage Data and Maximize Product Opportunity and Value

    Staged Clinical Development Approach to Leverage Data and Maximize Product Opportunity and Value Pruritus in Ped. Chol. { POC*in Liver Disease Adults Cholestatic Pivotal Pa (Primary Liver Disease PFIC Pivotal Biliary in Children Cirrhosis) Ph2 Ph2 Biliary Atresia *POC= Proof of Concept Ph2 2 BBIODEL

  23. Slide 23: Regulatory Strategy: Subpart H Approval for PFIC with Surrogate Endpoint

    Regulatory Strategy: Subpart H Approval for PFIC with Surrogate Endpoint, Post-Approval Long-Term Outcome Study e Seek accelerated approval for PFIC treatment using surrogate endpoint e Pre-IND FDA meeting confirms pruritus as viable surrogate; study planning ongoing e Long-term outcome study to be

  24. Slide 24: A Compelling Commercial Opportunity

    A Compelling Commercial Opportunity Multiple Rare Diseases with No Approved Drug Options* Pediatric Cholestatic PFIC Pruritus Biliary Atresia 2 30,000 ) zy mam ee ™ FS A 40,000 — ze] é 5 20,000 6 2 5,000 ; ~ ft 4 Ey ts = a & 7 4 oo 2015 2019 2024 2029 ° - or -_ 7 * 2015 2020 2025 2030 2015 2020 2025

  25. Slide 25: Pipeline Programs

    = 4 Pipeline Programs BBIoDEL Albjzeg<

  26. Slide 26: Phase 3 Ongoing in Japan; Favorable US/EU Data Generated, Interaction with FDA

    Phase 3 — Ongoing in Japan; Favorable US/EU Data Generated, Interaction with FDA for US Pivotal Program Underway ‘Commercial EA Pharma (Eisai/Ajinomoto)* Albireo (seeking partner) Rights Data Ph2: n=163; primary endpoint met with | Ph2: n=190; primary endpoint met with high high statistical signific

  27. Slide 27: First and Only Large Bowel-Acting Agent for CIC that Increases Both Secretion AND Motility

    First and Only Large Bowel-Acting Agent for CIC that Increases Both Secretion AND Motility + The market opportunity... © 156% dollar Rx market growth since 2011 + The data... © Strong US Ph2b efficacy data with favorable AE profile © Ph2b results reproduced in Japan, leading to rapid advancement to

  28. Slide 28: Unique Dual Impact and Site of Action Provides Substantial Commercial Differentiation

    Unique Dual Impact and Site of Action Provides Substantial Commercial Differentiation { =) Small intestinal secretory agent | Lubiprostone (Amitiza®) Chloride channel Approved Takeda/Mylan agonist 2015 Sales ~$311M Linaclotide (Linzess®) Chloride channel Approved Siaell liteallnel eowtcten again Iro

  29. Slide 29: Readout from Phase 3 Study in Japan Expected Q4 2016

    Readout from Phase 3 Study in Japan Expected Q4 2016 Phase 2b Primary Endpoint in Japan * Gl rights licensed to Ajinomoto Change in Number of Weekly SBM from Baseline Pharmaceuticals in Japan* 10 + Ajinomoto Pharma combines with whe Eisai’s Gl business in 2016 to create 8 ~ EA Pharma, aiming to be J

  30. Slide 30: Interaction with FDA for US Pivotal Program Underway

    Interaction with FDA for US Pivotal Program Underway Ph2 Double Blind, Placebo Ph3 Double Blind, Placebo Controlled ECHO Studies by Licensee Controlled Study (n=190) (n=690, 40% of planned enrollment; studies stopped early due to CTM distribution Issue unrelated to drug performance) q we | Overall C

  31. Slide 31: A3384: Positioned to Become First Drug Approved for Bile Acid Malabsorption Disease

    A3384 Positioned to Become First Drug Approved for Bile Acid Malabsorption Disease * The market opportunity. © ~4m patients estimated in major markets © No approved drug, difficult-to-take resins with poor DDI profiles used off label + The science... ©. Designed to deliver cholestyramine directly to

  32. Slide 32: NASH Platform: Albireo Data Shows IBAT Inhibition Benefits Four Principal Hallmarks

    NASH Platform: Albireo Data Shows IBAT Inhibition Benefits Four Principal Hallmarks Improved Cholesterol Profile Decreased Insulin Resistance ae a 5 35 zg a 3 27 5 rt 5 Phos 3 6 1] eptaceto +005 pcos Ba "ae ams} H8me Chey et alAm J Gastroenterol 2011, Elobibat @-veek Phase 20 study a using eta BMC C

  33. Slide 33: Significant NAS Reduction with A4250 in Validated Preclinical NASH Model

    Significant NAS Reduction with A4250 in Validated Preclinical STAM™ Model Matches Prior Findings with Obeticholic Acid A4250 OCA OCA Significantly Reduces NAS ANAS: - 0.9 ANAS: -0.9 in Phase 2 study 10 mg/kg, 3 wks 10 mg/kg, 5 wks 25 mg OCA or placebo for 72 weeks % patients with improvement in NAS

  34. Slide 34: SBIoDEL Albiceg<

    SBIoDEL Albiceg<

  35. Slide 35: Strong Patent and Regulatory Protections

    Strong Patent and Regulatory Protections PEP Exaly Ped. Exclusivity Composition of Matter September 2022 2025 MOU IBAT inhibitors to treat liver November 2031 2033 diseases (pending) MOU IBAT inhibitors in November 2031 2033 combination with bile acid binders to treat liver diseases (pending) (Orpha

  36. Slide 36: Significant News Flow and Near-Term Milestones Projected

    Significant News Flow and Near-Term Milestones Projected Report data from ongoing Ph2 Trial of A4250 in Pediatric 2H 2016 Liver Disease Report data from ongoing Ph3 Trial of Elobixibat in Japan Q4 2016 A4250 End of Phase 2 FDA Meeting Q4 2016 JNDA filing for Elobixibat Q1 2017 Report data from plann

  37. Slide 37: Albireo

    Albireo Innovative Science + Deep Pipeline + Experienced Management + Leader in the development of bile acid modulators to treat liver and GI diseases + Three clinical assets (lead Ph2 orphan and Ph3 constipation product candidates) + Multiple near-term inflection opportunities + Funding expected to

  38. Slide 38: Thank you

    SBIODEL Thank you NASDAQ: BIOD | May 25, 2016 Albireo

  39. Slide 39: Summary

  40. Slide 40: A4250 — A Potent Compound with Strong Dose Response

    A4250 — A Potent Compound with Strong Dose Response 4250 ‘SHP625 (LUM001) Serum bile acids AUC °*% Day 7 ‘Serum bile acids AUC 1% Day 14 8 8 Pacebo " imeM2s0 3mgan2so ees as se me ‘Serum Bile Acids AUCO-12h (umol x b/) a8 ‘Serum Bile Acids AUC (mmole /t) Dose, mgper day # AS Permanent cation ICq (hu

  41. Slide 41: Clinical Outcomes with Shire IBATi Validate Mechanism, Highlight Need for Superior Compound

    Clinical Outcomes with Shire IBATi Validate Mechanism, Highlight Need for Superior Compound PFIC: stat. sig. improvement in pruritus + baseline elevated liver enzymes normalized oNo statistically significant reduction in serum bile acids (primary endpoint), despite “profound decrease” in subset of p

Biodel — Merger or Acquisition (May 2016) on 6ix